Biotech Values

[biocqr]

AGN > Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

https://seekingalpha.com/pr/17270449-allergan-acquire-bonti-adding-new-neurotoxin-programs-medical-aesthetics-pipeline

Allergan (NYSE:AGN) has agreed to acquire Newport Beach, CA-based Bonti, a developer of fast-acting neurotoxin treatments for aesthetic and therapeutic applications.

Bonti's pipeline includes Phase 2-stage EB-001A (aesthetic) and EB-001T (therapeutic), a botulinum neurotoxin serotype E that has a two-to-four-week duration of effect which AGN says will be an attractive option for consumers, especially those considering an aesthetic treatment for the first time.

Under the terms of the agreement, AGN will pay $195M upfront plus milestones.